# Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

> **NCT04203485** · PHASE3 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 762 (estimated)

## Conditions studied

- PD-L1 Positive Non-small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Camrelizumab 200mg
- **DRUG:** Apatinib Mesylate 250mg
- **DRUG:** Pemetrexed disodium for injection
- **DRUG:** Paclitaxel injection
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT04203485
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-15
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-05-31
- **Target enrollment:** 762 (ESTIMATED)
- **Last updated:** 2020-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04203485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04203485, "Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04203485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*